BofA analyst Tazeen Ahmad initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $35 price target The clinical-stage biotech company’s, ALTO-207, is in development for treatment-resistant depression, backed by “encouraging” Phase 2a data, the analyst tells investors. If early efficacy and safety can be replicated, the firm thinks ALTO-207 “could become a differentiated treatment option in TRD, representing a meaningful commercial opportunity,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
- Alto Neuroscience participates in a conference call with H. C. Wainwright
- Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD
- Alto Neuroscience files to sell 6M shares of common stock for holders
- Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright